The St Vincent’s Hospital Heart Lung Transplant Unit has carried out the world’s first distant procurement of hearts donated after circulatory death (DCD). These hearts were subsequently resuscitated and then successfully transplanted into patients with end-stage heart failure.
Transplant Units until now have relied solely on donor hearts from brain-dead patients whose hearts are still beating. The use of DCD hearts, where the heart is no longer beating, represents a paradigm shift in organ donation and will herald a major increase in the pool of available hearts for transplantation.
St Vincent’s has recently transplanted two patients using DCD hearts both of whom have recovered extremely well. The DCD transplants were carried out following pioneering basic and translational research undertaken by the Victor Chang Cardiac Research Institute and St Vincent’s Hospital, who have jointly developed a special preservation solution that together with the use of a novel portable console to house, resuscitate and transport donor hearts; has made this milestone achievable.
The ex vivo Organ Care System (OCS – TransmedicsTM) involves the Transplant retrieval team connecting the donor heart to a sterile circuit where it is kept beating and warm thereby limiting the detrimental effects of cold ischaemia (a period where the heart is dormant without oxygen and nutrients) that occurs with the standard organ preservation mode of packing the heart on ice in an Esky. Once housed inside the portable device, the heart is reanimated, preserved and able to be functionally assessed until it is ready to be placed inside the recipient.
Coined the “Heart in a box”, for the past several months the OCS has provided the transplant surgeons greater versatility with regard to both organ preservation and resuscitation. This has enabled the St Vincent’s Transplant Unit to conduct several regular heart transplants this year through more long distance organ retrievals and most importantly, retrieval of “marginal hearts”, that is, brain death hearts previously regarded as being unsuitable for transplantation.
This portable OCS technology will help significantly in mitigating the significant disparity that remains between the increasing number of patients with end-stage heart failure on the transplant waiting list and the number of suitable donor-hearts that are available. Whilst the use of DCD organs has already made an enormous positive impact on liver, kidney and lung transplantation, it has to date not been possible to use DCD hearts. This is the first time internationally that human heart transplantation has been achieved with hearts donated following circulatory death and procured at a distance with portable organ preservation technology.
The Latest on: End-stage heart failure
via Google News
The Latest on: End-stage heart failure
- Genes Play a Critical Role in Lupus Disease Outcomes in People from Ghanaon January 26, 2021 at 1:29 pm
Recent research out of Ghana underscores the powerful role genes can play in lupus disease outcomes, finding certain genetic risk factors that are more common in sub-Saharan African populations are ...
- This artificial heart could help keep people on transplant waiting lists aliveon January 22, 2021 at 1:32 pm
A French company called Carmat has created an artificial heart that could potentially save the lives of people with end-stage biventricular heart failure.
- Qatar- Heart Hospital performs over 500 cardiac surgical procedures in 2020on January 21, 2021 at 4:40 am
Heart Hospital, a member of Hamad Medical Corporation (HMC), safely performed 527 cardiac surgical procedures in 2020 amid the Covid-19 pandemic. Since 2012, surgical teams at the hospital have ...
- EU Approves Sales Of First Total Artificial Hearton January 21, 2021 at 3:28 am
A total artificial heart (TAH) has been greenlit for sales in the European Union after approval for use in patients who desperately need a transplant, but ...
- Heart Hospital performs over 500 cardiac surgical procedures in 2020on January 20, 2021 at 10:32 am
Heart Hospital, a member of Hamad Medical Corporation (HMC), safely performed 527 cardiac surgical procedures in 2020 amid the Covid-19 pandemic.
- This Artificial Heart Will Soon Be on the Market in Europeon January 20, 2021 at 7:00 am
Embedded electronics, microprocessors, and sensors regulate responses to the patient’s activity and adjust blood flow accordingly.
- CARMAT: 2021 Financial Calendaron January 18, 2021 at 1:45 pm
Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced artificial heart project, aiming ...
- iTHRIV announces recipients of health research pilot projectson January 14, 2021 at 9:39 pm
The Clinical and Translational Science Award (CTSA) hub partnership between Virginia Tech, the University of Virginia, Carilion Clinic, and Inova Health System has awarded $200,000 in funding to five ...
- iTHRIV announces health research pilot project recipientson January 14, 2021 at 9:20 am
Multi-institutional teams of scientists, physicians, and engineers will study Parkinson's disease, celiac disease, pediatric heart transplant, pediatric telemedicine, and epilepsy.
- APAC Kidney Disease Industry to 2027 - Increasing Incidences of ESRD (End-Stage Renal Disease) is Driving Growth - ResearchAndMarkets.comon January 13, 2021 at 3:53 am
According to this report the Asia Pacific kidney disease market is expected to reach $37.204.4 million in 2027 from $21,930.1 in 2019. The market is estimated to grow with a CAGR ...
via Bing News